Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

Inclusion Criteria:

* Signed the informed consent form.
* Male, aged ≥ 18 years.
* Life expectancy ≥ 3 months.
* Histologically or cytologically confirmed prostate adenocarcinoma.
* Metastatic prostate cancer.
* Organ function meet protocol requirements.
* Recovered from all reversible AEs related to previous anticancer treatments.

Exclusion Criteria:

* Previous treatment with the following drugs:

  1. AR PROTAC class drugs.
  2. Other systemic anticancer therapy within 3 weeks or 5 half-lives prior to the first administration of the study treatment.
  3. Taditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first administration of the study treatment.
  4. Drugs that may cause drug-drug interactions (DDI) with the study treatment.
  5. Drugs known to prolong the QT interval or potentially cause torsades de pointes ventricular tachycardia
* Presence of central nervous system metastases, leptomeningeal metastasis, or spinal cord compression.
* Radiation therapy involving more than 25% of bone marrow within 4 weeks prior to the first administration of the investigational medicinal product; local radiation therapy within 2 weeks prior to the first administration of the investigational medicinal product.
* Treatment with other investigational drugs or major surgery within 4 weeks.
* Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption.
* With severe cardiovascular or cerebrovascular diseases or related history.
* Active, uncontrolled infections.
* History of other significant malignancies within 5 years.
* Moderate to severe pulmonary disease significantly affecting lung function.
* According to the investigator's judgment, there are comorbidities that seriously endanger subject safety or affect the subject's ability to complete the study.
* Allergy to any of the investigational medicinal products or their components.